A new drug aimed at tackling obesity has been undergoing trials that have revealed a reduction in weight loss by up to two stone in six months.
The results, published in The Lancet found that the drug ‘Cragrilintide’ reduces body weight by up to 11% and is taken once a week as an injection.
The drug allows people to feel full and less hungry and eat less as a result.
While speaking on Newstalk Breakfast this morning, obesity specialist at St. Vincent’s University Hospital Professor Carel le Roux stated that the drug works on the part of the brain “that has the disease of obesity that makes people feel more hungry or less satisfied”.
Trials for the drug took place in ten countries, including Ireland, over a period of six months in 2019 with 706 participants split into seven groups.
One group was administered a placebo while the other was given an obesity drug, with the remaining five groups being administered different strengths of Cragrilintide.
Those who were administered the higher dose of the drug were found to have a reduction in body weight of between 9% and 11%, while lower doses resulted in a 6% reduction in body weight.
Not everybody with obesity will be able to qualify for the drug but those who do qualify will be enabled to live longer and better, according to le Roux.